Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis DOI Creative Commons
Margherita Nosadini, Michael Eyre, Erika Molteni

et al.

JAMA Neurology, Journal Year: 2021, Volume and Issue: 78(11), P. 1333 - 1333

Published: Sept. 20, 2021

Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments combinations remains unclear.To map use safety immunotherapies NMDARE, identify early predictors poor functional outcome relapse, evaluate changes disease over 14 years since first reports assess Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score.Systematic search PubMed from inception January 1, 2019.Published articles including patients NMDARE positive NMDAR antibodies available individual data.Individual patient data on immunotherapies, clinical characteristics at presentation, course, final (modified Rankin Scale [mRS] score) were entered into multivariable logistic regression models.The planned study 12 months onset (good, mRS score 0 2; poor, greater than 2) monophasic course (absence relapse 24 or later onset).Data 1550 652 evaluated. Of these, 1105 1508 (73.3%) female 707 1526 (46.3%) 18 younger onset. Factors event that significantly associated good included adolescent age first-line treatment therapeutic apheresis, corticosteroids plus intravenous immunoglobulin (IVIG), IVIG apheresis. 2 65 older onset, intensive care unit admission, extreme delta brush pattern electroencephalography, lack within 30 days maintenance for 6 more. nonrelapsing rituximab Adolescent was relapsing disease. Rituximab increased 13.5% (52 384; 2007 2013) 28.3% (311 1100; 2013 2019) (P < .001), concurrent a falling rate same period (22% [12 55] 2008 earlier; 10.9% [35 322] 2017 later; P = .006). Modified NEOS (including 4 5 original items) probability status 1 year (20.1% [40 199] points; 43.8% [77 176] 3 .05).Factors influencing are different need be considered independently development evidence-based optimal management guidelines NMDARE.

Language: Английский

Multiple sclerosis DOI
Dejan Jakimovski, Stefan Bittner, Robert Zivadinov

et al.

The Lancet, Journal Year: 2023, Volume and Issue: 403(10422), P. 183 - 202

Published: Nov. 7, 2023

Language: Английский

Citations

181
Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk DOI Open Access
Katarina Tengvall, Jesse Huang, Cecilia Hellström

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2019, Volume and Issue: 116(34), P. 16955 - 16960

Published: Aug. 2, 2019

Multiple sclerosis (MS) is a chronic inflammatory, likely autoimmune disease of the central nervous system with combination genetic and environmental risk factors, among which Epstein-Barr virus (EBV) infection strong suspect. We have previously identified increased autoantibody levels toward chloride-channel protein Anoctamin 2 (ANO2) in MS. Here, IgG antibody reactivity ANO2 EBV nuclear antigen 1 (EBNA1) was measured using bead-based multiplex serology plasma samples from 8,746 MS cases 7,228 controls. detected anti-ANO2 (P = 3.5 × 10-36) 14.6% 7.8% controls being seropositive (odds ratio [OR] 1.6; 95% confidence intervals [95%CI]: 1.5 to 1.8). The increase ANO2-seropositive individuals dramatic when also exposed 3 known factors for MS: HLA-DRB1*15:01 carriage, absence HLA-A*02:01, high anti-EBNA1 (OR 24.9; 95%CI: 17.9 34.8). Reciprocal blocking experiments EBNA1 peptides demonstrated cross-reactivity, mapping [aa 140 149] 431 440]. HLA gene region associated HLA-DRB1*04:01 haplotype negatively seropositivity 0.6; 0.5 0.7). Anti-ANO2 were not patients other inflammatory cohorts. influence fact that specific production usually needs T cell help provides indirect evidence autoreactivity propose hypothesis where immune through molecular mimicry contributes etiopathogenesis

Language: Английский

Citations

174
The lung microbiome regulates brain autoimmunity DOI

Leon Hosang,

Roger Cugota Canals,

Felicia Joy van der Flier

et al.

Nature, Journal Year: 2022, Volume and Issue: 603(7899), P. 138 - 144

Published: Feb. 23, 2022

Language: Английский

Citations

170
Rituximab for the treatment of multiple sclerosis: a review DOI Open Access
Clara Grazia Chisari,

Eleonora Sgarlata,

Sebastiano Arena

et al.

Journal of Neurology, Journal Year: 2021, Volume and Issue: 269(1), P. 159 - 183

Published: Jan. 8, 2021

Language: Английский

Citations

154
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis DOI Creative Commons
Margherita Nosadini, Michael Eyre, Erika Molteni

et al.

JAMA Neurology, Journal Year: 2021, Volume and Issue: 78(11), P. 1333 - 1333

Published: Sept. 20, 2021

Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments combinations remains unclear.To map use safety immunotherapies NMDARE, identify early predictors poor functional outcome relapse, evaluate changes disease over 14 years since first reports assess Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score.Systematic search PubMed from inception January 1, 2019.Published articles including patients NMDARE positive NMDAR antibodies available individual data.Individual patient data on immunotherapies, clinical characteristics at presentation, course, final (modified Rankin Scale [mRS] score) were entered into multivariable logistic regression models.The planned study 12 months onset (good, mRS score 0 2; poor, greater than 2) monophasic course (absence relapse 24 or later onset).Data 1550 652 evaluated. Of these, 1105 1508 (73.3%) female 707 1526 (46.3%) 18 younger onset. Factors event that significantly associated good included adolescent age first-line treatment therapeutic apheresis, corticosteroids plus intravenous immunoglobulin (IVIG), IVIG apheresis. 2 65 older onset, intensive care unit admission, extreme delta brush pattern electroencephalography, lack within 30 days maintenance for 6 more. nonrelapsing rituximab Adolescent was relapsing disease. Rituximab increased 13.5% (52 384; 2007 2013) 28.3% (311 1100; 2013 2019) (P < .001), concurrent a falling rate same period (22% [12 55] 2008 earlier; 10.9% [35 322] 2017 later; P = .006). Modified NEOS (including 4 5 original items) probability status 1 year (20.1% [40 199] points; 43.8% [77 176] 3 .05).Factors influencing are different need be considered independently development evidence-based optimal management guidelines NMDARE.

Language: Английский

Citations

143